Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced that the U.S. Food and Drug Administration (FDA) has allowed an IND (Investigational New Drug) for the Company's lead cancer drug candidate liposomal Grb-2...
China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production...
China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production...